Dooks	NI-
Docket	INO.

Declaration and Power of Attorney For Patent Application English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

-	if plural names are	ventor (if only one name is listed belo listed below) of the subject matter w entitled	· ·
PEPTIDES FOR TREATM	MENT OF INFLAMM	IATION AND SHOCK	
the specification of whi	ch		
(check one)			
☐ is attached hereto.			
was filed on 13 Aug	gust 1997	as United States Application No	. or PCT International
Application Number	PCT/CA97/00568	<u> </u>	
and was amended	on		
	•	(if applicable)	·
		derstand the contents of the above in the above in the above in the above.	dentified specification,
•		United States Patent and Trademark ility as defined in Title 37, Code of	
Section 365(b) of any any PCT International States, listed below an	foreign application application which d have also identifulticate or PCT Inter	nder Title 35, United States Code, (s) for patent or inventor's certificate designated at least one country died below, by checking the box, any ernational application having a filing of	, or Section 365(a) of other than the United foreign application for
Prior Foreign Application	on(s)		Priority Not Claimed
9617021.2	GB	13/08/96	
(Number)	(Country)	(Day/Month/Year Filed)	
(Number)	(Country)	(Day/Month/Year Filed)	
(Hamber)	(Country)	(Suy/Months Four Filed)	
(Number)	(Country)	(Day/Month/Year Filed)	
		· · · · · · · · · · · · · · · · · · ·	

(Application Serial No.)	(Filing Date)	· . ^
(Application Serial No.)	(Filing Date)	
	•	
(Application Serial No.)	(Filing Date)	
section 365(c) of any PCT Internationsofar as the subject matter of eather subject matter of eather states or PCT International I.S.C. Section 112, I acknowledge office all information known to medication 1.56 which became availab	ional application designating ach of the claims of this application in the manner per the duty to disclose to the error to be material to patentable between the filing date of	any United States application(s), of the United States, listed below an epication is not disclosed in the pricorovided by the first paragraph of 3 United States Patent and Tradema collity as defined in Title 37, C. F. F. the prior application and the nation
Section 365(c) of any PCT Internations of as the subject matter of ear Juited States or PCT International J.S.C. Section 112, I acknowledge office all information known to me	ional application designating ach of the claims of this application in the manner per the duty to disclose to the error to be material to patentable between the filing date of	y the United States, listed below an plication is not disclosed in the pricorovided by the first paragraph of 3 United States Patent and Tradema bility as defined in Title 37, C. F. R
Section 365(c) of any PCT Internations of as the subject matter of ear Inited States or PCT International J.S.C. Section 112, I acknowledge office all information known to medication 1.56 which became availab	ional application designating ach of the claims of this application in the manner per the duty to disclose to the error to be material to patentable between the filing date of	g the United States, listed below an plication is not disclosed in the priorovided by the first paragraph of 3 United States Patent and Tradema pility as defined in Title 37, C. F. F. the prior application and the nation (Status)
ection 365(c) of any PCT International association as the subject matter of earlied States or PCT International S.C. Section 112, I acknowledge office all information known to me ection 1.56 which became availabing PCT International filing date of the	ional application designating ach of the claims of this application in the manner per the duty to disclose to the error to be material to patentable between the filing date of its application:	g the United States, listed below an plication is not disclosed in the priorovided by the first paragraph of 3 United States Patent and Tradema pility as defined in Title 37, C. F. R. the prior application and the nation
ection 365(c) of any PCT International assort as the subject matter of earlited States or PCT International S.C. Section 112, I acknowledge office all information known to meetion 1.56 which became availabing the pCT International filing date of the	ional application designating ach of the claims of this application in the manner per the duty to disclose to the error to be material to patentable between the filing date of its application:	g the United States, listed below an plication is not disclosed in the priorovided by the first paragraph of 3 United States Patent and Tradema pility as defined in Title 37, C. F. R. the prior application and the nation (Status) (patented, pending, abandoned)
ection 365(c) of any PCT International sofar as the subject matter of earlited States or PCT International S.C. Section 112, I acknowledge office all information known to me ection 1.56 which became available PCT International filing date of the (Application Serial No.)	ional application designating ach of the claims of this application in the manner per the duty to disclose to the er to be material to patentable between the filing date of its application: (Filing Date)	g the United States, listed below an plication is not disclosed in the priorovided by the first paragraph of 3 United States Patent and Tradema pility as defined in Title 37, C. F. R. the prior application and the nation (Status) (patented, pending, abandoned)
ection 365(c) of any PCT International asofar as the subject matter of earnited States or PCT International S.C. Section 112, I acknowledge office all information known to me ection 1.56 which became available PCT International filing date of the (Application Serial No.)	ional application designating ach of the claims of this application in the manner per the duty to disclose to the er to be material to patentable between the filing date of its application: (Filing Date)	g the United States, listed below an plication is not disclosed in the priorovided by the first paragraph of 3 United States Patent and Tradema pility as defined in Title 37, C. F. R. the prior application and the nation (Status) (patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

William L. Mathis (17,337); Peter H. Smolka (15,913); Robert S. Swecker (19,885); Platon N. Mandros (22,124); Robert M. Schulman (31,196); William C. Rowland Benton S. Duffett, Jr. (22,030); Joseph R. Magnone (24,239); Norman H. Stepno (22,716); Ronald L. Grudziecki (24,970); Frederick G. Michaud, Jr. (26,003); (32,344); William H. Benz (25,952); Peter K. Skiff Alan E. Kopecki (25,813); Regis E. Slutter (26,999); Samuel C. Miller, III (27,360); Ralph L. Freeland, Jr. (16,110); Robert G. Mukai (28,531); George A. Hovanec, F. Swiss (30,113) Jr. (28,223); James A. LaBarre (28,632); E. Joseph Gess (28,510); R. Danny Huntington (27,903); Eric H. Weisblatt (30,505); James W. Peterson (26,057);

Teresa Stanek Rea (30,427); Robert E. Krebs (25,885); (30,888); T. Gene Dillahunty (25,423); Anthony W. Shaw (30,104); Patrick C. Keane (32,858); Bruce J. Boggs, Jr. (31,917); Richard J. McGrath (29,195); Matthew L. Schneider (32,814); Michael G. Savage (32,596); Gerald

Send Correspondence to: Burns, Doane, Swecker & Mathis, LLP

P.O. Box 1404

Alexandria, Virginia 22313-1404

Direct Telephone Calls to: (name and telephone number)

Teresa Stanek Rea at (703) 836-6620

Full name of sole or first inventor MATHISON, Ronald	· ·	
Sole or first inventor's signature		Ap pil 7, 1998×
Residence Calgary, Alberta, Canada		
Citizenship Canada		
Post Office Address 208 Silverhill Crescent NW		
Calgary, Alberta T3B 3Y3 Canada		

Full name of second inventor, if any DAVISON, Joseph S.				•
Second inventor's signature X	•	April M	Date 1998	×
Residence Calgary, Alberta, Canada				
Citizenship Canada				
Post Office Address 600 Dalmeny Hill NW				
Calgary, Alberta T3A 1R3 Canada				

Third inventor's signature					Mrs.	16 /98 ×
Residence Edmonton, Alberta, Canada					igni	(10/10/
Citizenship Canada	 				· · · · ·	
Post Office Address 14015 Valleyview Drive						
Edmonton, Alberta T5R 5T9 Canad	a					
			,			
Full name of fourth inventor, if any MOORE, Graham		•	•			
Fourth inventor's signature Warmen Residence		· ·	,			April 7/98
Calgary, Alberta, Canada Citizenship						· .
Canada						
Post Office Address 1762 1A Avenue NW			-	-		
Calgary, Alberta T2N 0B2 Canada						
Full and a fifth invalidation of the second						
Full name of fifth inventor, if any					•	
Fifth inventor's signature						Date
Residence						
Citizenship						
Post Office Address						
Post Office Address						
Post Office Address						
Post Office Address Full name of sixth inventor, if any						
						Date
Full name of sixth inventor, if any						Date
Full name of sixth inventor, if any Sixth inventor's signature						Date
Full name of sixth inventor, if any Sixth inventor's signature Residence						Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) MAILSTOP: SEQUENCE LISTING
Ronald MATHISON et al.)
Application No.: Not Yet Assigned) Oroup Art Unit: Not Yet Assigned
Filed: February 9, 2004) Examiner: Not Yet Assigned
For: PEPTIDES FOR TREATMENT OF	<i>)</i>)
INFLAMMATION AND SHOCK)

DECLARATION PURSUANT TO 37 C.F.R. §§ 1.821-1.825

MAILSTOP: SEQUENCE LISTING Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

- I, Susan M. Dadio, declare as follows:
- 1. That, in compliance with 37 C.F.R. § 1.821(f), the content of the paper copy of the Sequence Listing included in the concurrently filed Preliminary Amendment, for incorporation into the specification, and the content of the substitute computer readable copy of the Sequence Listing filed on February 14, 2000 in parent Application No.: 09/051,395 are the same.
- 2. That the submission, filed in accordance with 37 C.F.R. § 1.821(g)[or (h)], does not include new matter [or go beyond the disclosure in the international application].

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and

Application Serial No. Not Yet Assigned
Attorney's Docket No. 024916-006
Page 2

further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued.

February 9, 2004

Date